Pink Sheet, Scrip

Drug Pricing eBook

25 May 2021

Tap into expert coverage of the complex world of drug pricing with insights from analysts at Scrip and Pink Sheet. This eBook includes vital information about issues affecting drug pricing for the US, EU, and other global markets, including patient access, regulatory issues, commercial challenges, value-based pricing, and more.

Topic Drug Pricing

Pink Sheet

US Drug Pricing Reform Post-Election: Scenarios To Consider And Lessons Learned

By Cathy Kelly 18 Nov 2020

Regardless of the outcomes of the US elections, drug pricing is likely to take a back seat to COVID as policy focus. But the pandemic does offer pharma an opportunity for partnerships with payers on health outcomes. Commonwealth Fund’s Liz Fowler, South Capitol’s John O’Brien and ICER’s Steve Pearson discuss where drug pricing stands in public opinion, whether policies embraced by President Trump will have staying power, and the conditions needed in the policy environment for major change.

Topic US Election 2020 Policy & Regulation Drug Pricing

Scrip

Quick Listen: Scrip's Five Must-Know Things

By Ian Haydock 02 Oct 2020

Join us for an audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.

Topic Clinical Trials Drug Pricing Research & Development

Pink Sheet

'March In' Plan Unveiled By Democratic Think Tank: A Battle Biopharma Would Welcome?

By Michael McCaughan 25 Sep 2020

In sign of how much has changed in four years, industry might be better off if Biden takes CAP’s advice and launches ‘march-in’ actions to address pricing of COVID products.

Topic US Election 2020 Drug Pricing